Demeclocycline

Generic Name
Demeclocycline
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H21ClN2O8
CAS Number
127-33-3
Unique Ingredient Identifier
5R5W9ICI6O
Background

A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

Indication

Used primarily to treat Lyme disease, acne, and bronchitis. Also indicated (but rarely used) to treat urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia. One of its other registered uses is the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuret...

Associated Conditions
Relapsing fever caused by Borrelia recurrentis, Tularemia, Severe Acne Vulgaris, Psittacosis, Urinary Tract Infection, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), Acute Intestinal amebiasis, Conjunctivitis caused by chlamydia, Yaws, Campylobacter Infection, Rickettsia Infections, Anthrax, Listeria infection, Skin Infections caused by Staphylococcus Aureus, Chlamydial Infections, Clostridium Difficile Infection (CDI), Brucellosis, Bartonellosis, Chlamydia Trachomatis Infection, Gram-Negative Bacterial Infections, Plague, Actinomycosis, Sexually Transmitted Infections (STIs), Cholera (Disorder), Necrotizing ulcerative gingivostomatitis, Respiratory Tract Infections (RTI)
Associated Therapies
-

Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors

Phase 1
Conditions
Interventions
First Posted Date
2016-04-15
Last Posted Date
2016-04-15
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
40
Registration Number
NCT02740933
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

First Posted Date
2012-12-20
Last Posted Date
2015-10-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
69
Registration Number
NCT01753856
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath